Advertisement

Management of Adverse Events

  • Joseph Sadek
Chapter

Abstract

Adverse effects of stimulant medications include decreased appetite, sleep disturbance, headaches, irritability, nervousness, stomach upset, abdominal pain, nausea, abdominal discomfort, weight loss, tearfulness, stuttering, dizziness, increased heart rate and blood pressure.

Keywords

Psychotic Symptom ADHD Symptom Stimulant Medication ADHD Medication Appetite Suppression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

General References and Recommended Readings

  1. Australian draft guidelines 2009Google Scholar
  2. Brown RT, Amler RW, Freeman WS, Perrin JM, Stein MT, Feldman HM, Pierce K, Wolraich ML, American Academy of Pediatrics Committee on Quality Improvement; American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder (2005) Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 115(6):e749–e757PubMedCrossRefGoogle Scholar
  3. Gibson AP, Bettinger TL, Patel NC, Crismon ML (2006) Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother 40(6):1134–1142PubMedCrossRefGoogle Scholar
  4. Harpin VA (2008) Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006. Arch Dis Child Educ Pract Ed 93(2):58–65PubMedCrossRefGoogle Scholar
  5. Jensen P (2002) Longer term effects of stimulant treatments for attention-deficit/hyperactivity disorder. J Atten Disord 6(1):45–56Google Scholar
  6. Klein-Schwartz W (2002) Abuse and toxicity of methylphenidate. Curr Opin Pediatr 14(2):219–223PubMedCrossRefGoogle Scholar
  7. Kollins SH (2008) A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. Curr Med Res Opin 24(5):1345–1357. Epub 2008 Apr 1PubMedCrossRefGoogle Scholar
  8. Kratochvil CJ, Lake M, Pliszka SR, Walkup JT (2005) Pharmacological management of treatment-induced insomnia in ADHD. J Am Acad Child Adolesc Psychiatry 44(5):499–501PubMedCrossRefGoogle Scholar
  9. NICE guidelinesGoogle Scholar
  10. Pringsheim T, Steeves T (2011) Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev (4):CD007990Google Scholar
  11. Reeves G, Schweitzer J (2004) Pharmacological management of attention-deficit hyperactivity disorder. Expert Opin Pharmacother 5(6):1313–1320PubMedCrossRefGoogle Scholar
  12. Schonwald A, Lechner E (2006) Attention deficit/hyperactivity disorder: complexities and controversies. Curr Opin Pediatr 18(2):189–195PubMedCrossRefGoogle Scholar
  13. Stiefel G, Besag FM (2010) Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf 33(10):821–842PubMedCrossRefGoogle Scholar

ADHD Guidelines Available on the Internet

  1. American Psychological Association: http://www.apa.org/topics/adhd/index.aspx
  2. Australian ADHD Draft Guidelines: http://www.nhmrc.gov.au/guidelines/publications/ch54
  3. Canadian ADHD Guidelines: http://www.caddra.ca/cms4/
  4. National Institute for Health and Clinical Excellence (NICE): http://publications.nice.org.uk/attention-deficit-hyperactivity-disorder-cg72

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Joseph Sadek
    • 1
  1. 1.Department of PsychiatryDalhousie UniversityHalifaxCanada

Personalised recommendations